Dr Charles WOLER, Chairman, Independent Director

Curriculum: Medical Doctor, he holds a Master's degree and PhD in clinical pharmacology, and an MBA.

Career: He has over 35 years experience in the pharmaceutical, biotech and medtech industry in Europe and the United States. Board member of several biotech companies in France and Europe, including Vice Chairman of Genfit, Charles Woler brings to DEINOVE his broad expertise in strategic and operational management, business development and financing of pharmaceutical innovation.

Charles Woler was formerly Chairman and CEO of Roche France, President and CEO of Cadus Pharmaceutical in the United States (1995-1998), Chairman of Smithkline Beecham Europe and General Manager of Bouchara Group, before heading the company Neuro3d. Subsequently, he headed Endotis Pharma and then the Biomnis Group, acquired in 2015 by Eurofins Scientific. 

Mandates & Representations: Vice Chairman of France Biotech from 2004 to 2007. Member of the Inserm-Transfert Initiative Investment Committee from 2005 to 2010, which he was the Chairman of the advisory committee until 2012. 


Hervé BRAILLY, PhD, Independent Director

Curriculum: Graduated from of the Ecole des Mines de Paris (1983) and Doctor of Immunology, with a specialization in immuno-pharmacology.

Career: He has co-founded and managed for 17 years Innate Pharma, one of the world's leading specialists in immuno-oncology, and one of the success stories and first market capitalizations of French biotech, and is today Chairman of the Supervisory Board.

Previously, he was a researcher at Immunotech SA, a biotechnology start-up acquired in 1995 by Beckman-Coulter (1986-1994), and was in charge of marketing, business development and R&D at the same company (1994-1998). Beginning in 1998, Mr. Brailly was the director of a business unit of the company with 65 employees (R&D, marketing, manufacturing), with annual sales of 30 million U.S. dollars. He was the force behind the growth of the business activities in China for the same company between 1994 and 1998.

Mandates & Representations: Chairman of the Supervisory board of Innate Pharma. Member of the executive committee and treasurer of EurobioMed. Member of the development council of Marseille Provence Métropole. Member of the Strategy and Prospects committee of Aix Marseille University. Member of the investment committee of SATT Sud-Est. Chairman of Kervrant Biotech SAS


Michael CARLOS, Independent Director

President of Givaudan Fragrances

Curriculum: MBA from the Indian Institute of Management and a degree in chemical engineering from the Indian Institute of Technology.

Career: Michael Carlos has over 20 years of experience in the fragrance industry, and is Chairman of the Research Institute of Fragrance Materials and Vice-Chairman of the International Fragrance Association (IFRA) since 2012.

Since 2004, Michael Carlos has been the President of Givaudan Fragrances, one of the two divisions of the Swiss company Givaudan, the world leader in fragrances and flavors. In 2013, this division reported a turnover exceeding 2 billion CHF (~1.6 billion €). In 1999, he was appointed as Head of Consumer Products for this division. Michael Carlos previously managed the European Creative Centre in Argenteuil, after joining the Givaudan Group in 1984 as General Manager in Hong Kong. He began his career with the Tata Group where, notably, he assumed the responsibilities of General Manager in the Industrial Perfumes division.


Bernard FANGET, Independent Director

Vice President Process Development and Manufacturing of Abivax

Curriculum: Graduated in biochemistry from the University of Lyon, France.

Career: Vice President Process Development and Manufacturing of Abivax. He has over 30 years experience in pharmaceutical development, particularly in the development of vaccines and recombinant proteins.

Was previously Senior Vice President in charge of pharmaceutical development at Flamel Technologies and Corporate Vice President of the Global Industrialization division at Sanofi Pasteur. He has developed several large-scale production technologies and obtained registration of many vaccines.

Mandates & Representations: member of numerous working groups within the World Health Organization (WHO).


Dr Vincent JARLIER, Independent Director

Director of the Department of Bacteriology and Hygiene of the Pitié-Salpêtrière Hospital (Paris) 

Curriculum: Doctor of medicine, he holds a post-doc in microbiology and immunology.

Career: Heads the Department of Bacteriology and Hygiene of the Pitié-Salpêtrière Hospital (Paris) since 1996. He is an internationally recognized expert on hospital-acquired infections (HAI) and the fight against resistant and multi-resistant bacteria. His expertise will be invaluable for DEINOVE in the development of its research strategy for innovative antibiotics to fight against resistant bacteria. Since 1994, Vincent Jarlier heads the French National reference centre for mycobacteria and resistance to anti-tuberculosis drugs, and since 2000, the survey of multi-resistant bacteria in French hospitals. 

Publications: Author and co-author of hundreds of publications.

Mandates & Representations: He founded in 1997 the National observatory for antimicrobial resistance (ONERBA) (coordinating 15 networks dedicated to antibiotic resistance survey) of which he coordinated the Scientific Committee (1997-2004) before becoming President (2006-2010). He was a member of the steering committee of the European Study Group for Antibiotic Resistance Survey (ESGARS) of ESCMID from 1999 to 2008, and is the French representative in the European Antimicrobial Resistance Survey System (EARS-Net), which he is a member of the steering committee and was the Chairman from 2011 to 2015.


Jean-François LABBE, representative of TVM Capital

TVM Capital is a shareholder of DEINOVE

Curriculum: MBA from HEC Business School, Paris (France).

Career: Founder and Chief Executive Officer of SpePharm Holding BV, a European specialty pharmaceutical company focused on niche hospital and specialists medicines from 2006 to 2012. Previously served as Chief Executive Officer of OTL Pharma SA from 2001 to 2004, then as Chief Operating Officer of ProStrakan UK from 2004 to 2005. President of Parke-Davis France/Warner-Lambert (Pfizer Group) from 1999 to 2001. He began his career at Hoechst Roussel in 1974, where he held various general management positions in Europe, South Africa and the United States. In 1995 he was appointed President Europe Middle East Africa and a member of the executive committee of Hoechst Marion Roussel until its merger with Aventis in 1999. 

Mandates & Representations: Board member at Nicox SA.


Christian PIERRET, company representative, Truffle Capital

Lawyer at the Paris Bar - Former Deputy Minister of Industry, Small and Medium Enterprises, Commerce and Crafts (1997 - 2002)

Curriculum: D.E.S. Economic Science (IEP Paris, 1970), ENA (1972).

Career: Dual career in politics and the private sector: General Reporter of the budget to the National Assembly (1981-1986), Chairman of the supervisory board of the Caisse des Dépôts (1988-1993), Vice-Chairman of the Group Accor (1993-1996). Deputy elected from the Vosges to the National Assembly from 1978 to 1993. Minister for Industry, SMEs, Commerce and Crafts 1997-2002, Christian PIERRET is the mayor of Saint Die des Vosges since 1989. Today, a lawyer at the Paris bar, Christian PIERRET is a specialist in the regulation of public companies, corporate law and business, public-private interfaces (especially in the field of environment) and European Law (concentration, competition, state aid). He is the originator of the "law PIERRET" in February 2002, which marked the opening of the French electricity and telecommunications markets to competition.

Publications: “Minister on the left - the magical and the real” - Ed Pré-aux-clerques, 2002. Numerous articles in economic, political and legal publications (Les Echos, La Tribune, Le Figaro, Le Monde, Financial Times...).

Awards & Distinctions:  Chevalier of the Legion of Honor. Chevalier of Academic Palms. Chevalier of Arts and Letters.


Dr Yannick PLÉTAN, Independent Director

Clinical development specialist 

Curriculum: Doctor of medicine (Paris Descartes University), pulmonologist and immunologist. He holds a Master’s degree in clinical pharmacology and pharmacokinetics, a diploma from the Advanced Leadership program (Harvard Business School) and one in Corporate Finance (HEC).

Career: Entering into the pharmaceutical industry in 1984 after leading a respiratory medicine department in a hospital and collaborating on research initiatives at INSERM for several years, Yannick Plétan headed the "Allergies and Respiratory Diseases" department at the headquarters in Rhone-Poulenc Rorer, before being appointed Medical Director of one of the French subsidiaries of Hoechst Roussel, companies which have now merged into the Sanofi Group. He was successively Chief medical officer, global Head of development and R&D strategy of the Pierre Fabre Research Institute; Head of the Medical and Scientific Division within the French subsidiary of the Pfizer group; and Country medical director of Roche France, where he founded the Roche Foundation for personalized healthcare in partnership with the University of Strasbourg. 

Publications & Patents: Author or co-author of several international guidelines for the WHO (World Health Organization) and ICH (International Conference on Harmonization), and several publications on clinical trial methodology, Yannick Plétan also collaborates with several European and American universities as a Guest Lecturer.


Dr Philippe POULETTY

CEO of Truffle Capital, founder and reference shareholder of DEINOVE

Curriculum: Doctor of Medicine (University Paris VI), immunologist (staff of the Pasteur Institute), Postdoctoral fellow at Stanford University, where in 1987 he published with his colleagues Larry Burg and John Boothroyd a technique for gene amplification now routinely used in laboratories all around the world.

Career: FIn 1989 founded SangStat, a company specializing in organ transplantation, acquired in 2002 by the American Genzyme for $600 million. Co-founder and CEO of Truffle Capital, a leading European venture capital company which now manages more than €520 million of investment in the sectors of information technology, life sciences and energy.

Patents: Philippe POULETTY is the author of 29 patents and member of the board of directors of 12 European biotechnology and medical device companies. He also founded three biotechnology companies in Europe and the United States.

Mandates & Representations: Honorary President and founder of France Biotech (French association of biotechnology). Former Vice-President of the European Association for the biotechnology industry EuropaBio.

Awards & Distinctions: 1999 laureate of the American Liver Foundation. Chevalier of the Legion of Honor.